GLP-1 receptor agonists slow gastric emptying and act on appetite regulation. In direct-to-consumer telehealth they are usually supplied as compounded semaglutide or tirzepatide, in injectable or oral forms.
Dosing is titrated: the patient starts low and steps up over months as tolerance allows. This makes the therapy longitudinal rather than transactional, and it means the invoice has to follow the dose.
Eligibility is commonly screened on BMI thresholds with comorbidity adjustments, plus contraindication screening at intake.
GLP-1 is the largest category in direct-to-consumer telehealth. Its operational demands, titration, cold chain and check-in gated refills, are also the ones generic subscription infrastructure handles worst.
GLP-1, in practice
Where clinically appropriate and permitted, prescribed by a provider licensed in the patient's state and dispensed by a licensed compounding pharmacy. Availability is subject to regulatory conditions that change, so patient-facing materials must describe compounded medications accurately.